In patients with prostate cancer, MDSCs accumulate in the blood as prostate cancer progresses and inhibit the proliferation of autologous CD8+ T cells and the production of interferon-γ (IFN-γ) and granzyme-B [53]. Here, CD8A is linked to prostate carcinoma.